Condition (MeSH)
Leprosy, Multibacillary
ClinicalTrials.gov lists 8 trials for Leprosy, Multibacillary or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
5 of the 8 trials are tagged with Leprosy, Multibacillary itself; the rest are tagged with a narrower condition beneath it.
When did Leprosy, Multibacillary trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 1 |
| 2022 | 1 |
| 2018 | 1 |
| 2010 | 1 |
| 2006 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Leprosy, Multibacillary trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 2 |
| Expanded access | 1 |
How many Leprosy, Multibacillary trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Completed | 4 |
| No longer available | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Leprosy, Multibacillary trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Caja Costarricense de Seguro Social | 1 |
| Janssen Research & Development, LLC | 1 |
Which publications cover Leprosy, Multibacillary? (6)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Bedaquiline Monotherapy for Multibacillary Leprosy. | The New England journal of medicine | 2024 | Yes |
| <i>Mycobacterium leprae</i>-Specific Antibodies in Multibacillary Leprosy Patients Decrease During and After Treatment With Either the Regular 12 Doses Multidrug Therapy (MDT) or the Uniform 6 Doses MDT. | Frontiers in immunology | 2018 | Yes |
| Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients. | PLoS neglected tropical diseases | 2017 | Yes |
| Using methotrexate to treat patients with ENL unresponsive to steroids and clofazimine: a report on 9 patients. | Leprosy review | 2013 | Yes |
| Comparing the clinical and histological diagnosis of leprosy and leprosy reactions in the INFIR cohort of Indian patients with multibacillary leprosy. | PLoS neglected tropical diseases | 2012 | Yes |
Showing 5 of 6 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.
Not computed for conditions with fewer than 10 trials: drugs tested.